UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 8, 2016**

FLAMEL TECHNOLOGIES S.A.

(Exact name of registrant as specified in its charter)

Republic of France	**000-28508**	**98-0639540**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Parc Club du Moulin à Vent **33, avenue du Docteur Georges Levy** **69200 Vénissieux France**	**Not Applicable**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **011 +33 472 78 34 34**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On March 14, 2016, Flamel Technologies S.A. (the "Company") intends to make a presentation at the 28th Annual ROTH Conference in Dana Point, California. A copy of the Company's complete slide presentation to be used at the Conference is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. As previously announced, the Company's presentation will be webcast live and can be accessed by visiting the Investor section of the Company's website at http://www.flamel.com/investors. A replay of the presentation, together with the complete slide presentation, will also be available and archived for at least 30 days on the website following the event.

The information responsive to Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On March 8, 2016, the Company issued a press release, a copy of which is furnished as Exhibit 99.2 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1		Form of Slide Presentation of Flamel Technologies S.A. as of March 14, 2016.
99.2		Press release of Flamel Technologies S.A. dated as of March 8, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FLAMEL TECHNOLOGIES S.A.

By: /s/ Phillandas T. Thompson
Phillandas T. Thompson
Senior Vice President, General Counsel and
Corporate Secretary

Date: March 14, 2016

Exhibit Index

99.1		Form of Slide Presentation of Flamel Technologies S.A. as of March 14, 2016.
99.2		Press release of Flamel Technologies S.A. dated as of March 8, 2016


FLAMEL
technologies

Forward Looking Statements

This document includes statements concerning our operating results (including product sales), financial condition and product development milestones, which are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estimate," "plan," "will," "may," and the negative of these and similar expressions generally identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond Flamel's control and could cause actual results to differ materially from the results contemplated in such forward-looking statements. These risks, uncertainties and contingencies include the risks relating to: our dependence on a small number of products and customers for the majority of our revenues; the possibility that our Bloxiverz® and Vazculep® products, which are not patent protected, could face substantial competition resulting in a loss of market share or forcing us to reduce the prices we charge for those products; the possibility that we could fail to successfully complete the research and development for the two pipeline products we are evaluating for potential application to the FDA pursuant to our "unapproved-to-approved" strategy, or that competitors could complete the development of such products and apply for FDA approval of such products before us; our dependence on the performance of third parties in partnerships or strategic alliances for the commercialization of some of our products; the possibility that our products may not reach the commercial market or gain market acceptance; our need to invest substantial sums in research and development in order to remain competitive; our dependence on certain single providers for development of several of our drug delivery platforms and products; our dependence on a limited number of suppliers to manufacture our products and to deliver certain raw materials used in our products; the possibility that our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do; the challenges in protecting the intellectual property underlying our drug delivery platforms and other products; our dependence on key personnel to execute our business plan; the possibility that we may cease to qualify as a foreign private issuer, which would increase the costs and expenses we incur to comply with U.S. securities laws; and the other risks, uncertainties and contingencies described in the Company's filings with the U.S. Securities and Exchange Commission, including our annual report on Form 20-F for the year ended December 31, 2014, all of which filings are also available on the Company's website. Flamel undertakes no obligation to update its forward-looking statements as a result of new information, future events or otherwise, except as required by law.

Flamel Technologies Transformed

- Strong financial condition - profitable with strong cash flow and balance sheet
- Expanding commercialization product portfolio:
  - Two FDA approved products from the Eclat portfolio and a third expected in 2016
  - Four pediatric products via FSC Pediatrics acquisition
- Robust pipeline with several trials underway
- Expanded management team and commercial infrastructure

Mission: To build a diversified specialty pharmaceutical company that controls 100% of its drug development and future

Key Milestones Achieved in 2015

- ✓ Generated $173.2 million of revenues
- ✓ Profitable and cash flow positive for first time in Company's history
- ✓ Had successful meeting with FDA on Micropump® Sodium Oxybate
- ✓ Presented positive clinical data
  - **LiquiTime® guaifenesin**
  - **Trigger Lock™ hydromorphone**
  - **Medusa™ exenatide**
- ✓ Licensed exclusive U.S. rights to the LiquiTime® drug delivery platform to Perrigo for the Over-The-Counter (OTC) drug market
- ✓ Made key senior management team hires

2016 Expectations

- Integrate and market newly acquired FSC Pediatrics' products
- Complete and report data from Phase 1b study with Medusa™ exenatide in patients
- Commence patient registration and dosing for pivotal study of Micropump® sodium oxybate
- Launch UMD#3 following April 30th PDUFA date
- Begin licensing discussions for Trigger Lock™ platform
- Begin development of UMD #4*
- Corporate restructuring to geographically align business with location of intellectual property
- Achieve total product sales of $110-130 million, inclusive of FSC Pediatrics

*UMD is Flamel's Unapproved Marketed Drugs Strategy

Acquisition of FSC

FSC pediatrics

Strategic Rationale

In line with Company's strategy to become a fully integrated global specialty pharmaceutical company

FSC Pediatrics

- Commercial stage specialty pharmaceuticals company headquartered Charlotte, NC
- Provides commercial infrastructure to leverage for future products
- Provides new revenue stream from four FSC products and lessens dependence on Éclat products
- Positioned as a more attractive business partner for potential pediatric, geriatric and other assets

Cash Friendly Transaction Terms

- Fixed acquisition price totals $20.25 million paid over a five year period
  - $1 million annually for five years
  - Final payment in January 2021 of $15.0 million
- Variable consideration:
  - Royalties of 15% per annum on net sales of the current FSC products, up to $12.5 million for a period not exceeding ten years
- Expected 2016 revenues to approximate $10-$15 million
- Adjusted operating profit and cash flow neutral

FSC Sales Force Coverage



Marketed Products Portfolio

- Flamel's Products
- FSC Products

BLOXIVERZ® & VAZCULEP® Overview

Bloxiverz®

- Indication: Reverses neuromuscular blockades used in surgical procedures
- 1 of 3 approved versions of neostigmine methylsulfate injection
- Approximately 4 million vials sold annually in the United States*
- More details can be found at www.bloxiverz.com

Vazculep®

- Indication: Treatment of hypotension resulting primarily from vasodilation in the setting of anesthesia
- Form: 1 mL single use vials, 5 mL and 10 mL
- Market potential at end 2015*
  - 1mL vial – **5.7 million** 5mL vial – **1.2 million** 10mL vial – **0.2 million**
- More details can be found at www.vazculep.com

** IMS*

KARBINAL™ ER & CEFACLOR Overview

Karbinal™ ER
(carbinoxamine maleate) extended-release oral suspension | 4mg/5mL

- Licensed from Tris Pharma in August 2013
- Used for the treatment of seasonal and perennial allergic rhinitis in children 2 years of age and older
- Orange book patent protection through March 2029
- Market size for liquids in US estimated at $110 million

CEFACLOR
For Oral Suspension, USP
125 mg/5 mL · 250 mg/5 mL · 375 mg/5 mL

- Licensed from Yung Shin in March 2015
- 2nd generation Cephalosporin
- FDA-approved as therapeutically equivalent to Ceclor (significant brand recognition)
- Broad indication for children as young as 1 month of age; covers common pathogens
- Market size approximates $300 million

ACIPHEX® SPRINKLE™ Overview

- Licensed from Eisai in June 2014
- FDA approved AcipHex Sprinkle in March 2013 for the treatment of GERD in pediatric patients aged 1-11 years
- Launched promotional efforts in August 2014
- Market size for liquids in US estimated at $110 million
- Proton Pump Inhibitor (PPI) market is large and stable

AcipHex® Sprinkle™
(rabeprazole sodium)
Delayed-Release
Capsules

> 2.0 million annual prescriptions for patients aged 10-19 years
Market opportunity in this age group in excess of $750 million

>1.1 million annual prescriptions for patients aged 0-9 years
Market opportunity for this age group exceeds $400 million

FLEXICHAMBER® Overview

Flexichamber®
Anti-static Valved Collapsible Holding Chamber Rx Only

TRANSFORMING THE TRADITIONAL CHAMBER TO MOVE WITH THE LIFE OF A CHILD

- **Collapsible asthma spacer**
- **Internally developed with a 510 (K) clearance**
- **Market size estimated at $50 million**
- **Patents through 2028**
- **Patient benefits:**
  - ✓ Dynamic Portability
  - ✓ Optimal Performance
  - ✓ Simple Assembly
  - ✓ Enhanced Patient Care

Flamel's R&D Pipeline

- Micropump® sodium oxybate
- LiquiTime®
- Trigger Lock™ hydromorphone
- Medusa™ exenatide

Current Pipeline

Drug/ Technology	Indication	Proof of Concept	Pilot	Pivotal	Under Review	Approved	Sales Force
UD/UMD[1] #3	Undisclosed						Flamel
UD/UMD[1] #4	Undisclosed						Flamel
Sodium oxybate/ Micropump®	Narcolepsy						Flamel
Ibuprofen / LiquiTime®	Pain / Fever						Perrigo
Guaifenesin / LiquiTime®	Respiratory						Perrigo
Hydromorphone / Trigger Lock™	Pain						TBD
Exenatide/Medusa™	Diabetes						TBD

[1] UMD is Flamel's Unapproved Marketed Drugs Strategy that does not involve patented technology
UD = undisclosed

Micropump® Sodium Oxybate (FT218)

FT218 Overview

- Extended release oral solid formulation of sodium oxybate using Micropump®
- Studied in **40 healthy volunteers** across 2 studies
- **Profile is consistent** with the target of single dose before bedtime
- **Met with FDA mid 2015** and will submit IND and SPA during 1H 2016
- **Next step:** Phase III clinical trial application submission and initiation of pivotal study

Market Opportunity

- Jazz's Xyrem® FY2015 sales **could exceed $900 million***
- >~178,000 narcoleptic patients in the U.S.*
- Jazz reports **< 13,000 patients on treatment***
- Limited competition to date
- Micropump® sodium oxybate could benefit from improved formulation

* *GlobalData & JAZZ's 3Q'15 earnings call*

LiquiTime® OTC

Overview

- Extended release liquid oral suspension for treatment of pain and fever
- Ibuprofen & Guaifenesin oral suspension twice-daily dosing confirmed

Next Step:

- **Ibuprofen** – IND/CTA filing and pivotal trial initiation in 2H 2016
- **Guaifenesin** – Confirmatory PK study in 1H 2016

Market Opportunity

- Cough and cold U.S. market is estimated at **$6.5 billion annually**[1]
  - OTC ibuprofen-containing products recorded over $**490 million**[2] of sales
  - OTC guaifenesin-containing products recorded over **$440 million**[2] of sales
- LiquiTime® allows for combination of active ingredients
- **Exclusive U.S. rights licensed to Perrigo for the OTC drug market**

[1] Deutsche Bank
[2] IMS – U.S. sales

Trigger Lock™ Hydromorphone (FT227)

FT227 Overview

- Abuse-deterrent, extended-release, oral hydromorphone product for treatment of pain – technology is applicable to all opioids
- Positive results from two pilot PK studies in healthy volunteers announced in June 2015
- **Next step:** Meet with the FDA in 1H 2016; begin partnering discussions

Market Opportunity

- U.S. market for prescription painkillers (all forms) in 2015: **$6.5 billion** [1]
  - OxyContin® (extended-release oxycodone, Purdue): **$2.1 billion** [1]
  - ER hydromorphone (Exalgo® & generics) **$138 million** [1]
- Opioid prescriptions grew from ~76 million in 1991 to ~207 million in 2013 [2]
- ~2.1 million people suffered from substance use disorders related to prescription opioids[2]

[1] IMS [2] "America's Addiction to Opioids: Heroin and Prescription Drug Abuse" (National Institute on Drug Abuse, May 14, 2014)

Medusa™ Exenatide (FT228)

FT228 Overview

- Subcutaneous injection formulation of exenatide, a GLP-1 (glucagon-like peptide – 1) for treatment of Type 2 diabetes
- Interim phase I human clinical data reported in December 2015
- PK profile compatible with a release over one week in humans
- **Next step:** Complete Phase 1b study in 1H 2016

Market Opportunity

- Market opportunity: GLP-1 products recorded over **$3.1 billion*:**
  - **$2.3 billion** for Victoza® (once a day liraglutide, Novo Nordisk)
  - **$316 million** for Bydureon® (once-a-week exenatide, AstraZeneca)
  - **$294 million** for Byetta® (twice-a-day exenatide, AstraZeneca)

* *IMS – U.S. sales* in 2015

Flamel's Strengths

- Strong intellectual property
- Seasoned senior management
- Healthy financial situation

Strong Intellectual Property

Platform	US	Europe
Micropump®	July 2027	July 2023
LiquiTime®	September 2025	April 2023
Trigger Lock™	April 2027	May 2026 (pending)
Medusa™	June 2031	June 2027 (pending)

*New patents may be issued targeting each individual product in development where a Flamel drug delivery platform is applied to a specific molecule

Seasoned Senior Management

Name	Title	Appointed	Experience
Michael S. Anderson	**Chief Executive Officer**	2012	40+ years Pharma
Sandy Hatten	**Senior Vice President, Quality and Regulatory Affairs**	2015	30+ years Pharma
Phillandas T. Thompson, J.D., M.B.A.	**Senior Vice President, General Counsel**	2013	16+ years Legal
Mike Kanan	**Senior Vice President and Chief Financial Officer**	2015	30+ years Financial
Gregory J. Davis	**Vice President, Corporate and Business Development**	2015	20+ years Pharma
David Monteith, Ph.D.	**Vice President, Research and Development**	2014	25+ years Pharma
Dhiren D'Silva	**Vice President of Irish and European Operations**	2015	19+ years Business

Condensed Consolidated Statement of Operations
(Unaudited)

In USD million, except EPS and shares data (million)	Twelve months ended	
	December 31, 2015	December 31, 2014
Revenue	$ 173.2	$14.8
COGS	(10.9)	(3.4)
R&D	(25.6)	(17.3)
SG&A	(21.7)	(15.7)
Acquisition Royalty Payments	(32.2)	(1.7)
Adj Op. Profit (Loss) (non-GAAP)	82.8	(23.3)
Adj. Net Income (Loss) *(non-GAAP)*	43.1	(24.6)
Adjusted Diluted EPS	0.99	(0.68)

See Reconciliation of Non GAAP to GAAP in Appendix

Key Financial Metrics (Unaudited)

In Millions USD, Except Per Share Data:

Income Statement Metrics	Twelve months ended December 31,	
	2015	2014
Revenue	$ 173.2	$14.8
COGS	(10.9)	(3.4)
R&D	(25.6)	(17.3)
SG&A	(21.7)	(15.7)
Acquisition Earn-Out Payments/Accruals	(32.2)	(1.7)
Adj Op. Profit (Loss) *	82.8	(23.3)
Adj. Net Income (Loss) *	43.1	(24.6)
Adjusted Diluted EPS *	0.99	(0.68)

Balance Sheet Metrics	At December 31,	
	2015	2014
Cash & Marketable Securities	$ 144.8	$92.8
Goodwill & Intangible Assets	34.3	46.9
Long-term Contingent Consideration Liability	122.7	114.8

Cash Flow Metrics	Twelve months ended December 31,	
	2015	2014
Free Cash Flow *	$ 58.1	($13.7)

* = Non-GAAP. See Reconciliation of Non GAAP to GAAP in Appendix

Flamel Technologies Transformed

- Strong financial condition - profitable with strong cash flow and balance sheet
- Expanding commercialization product portfolio:
  - Two FDA approved products from the Eclat portfolio and a third expected in 2016
  - Four pediatric products via FSC Pediatrics acquisition
- Robust pipeline with several trials underway
- Expanded management team and commercial infrastructure

Mission: To build a diversified specialty pharmaceutical company that controls 100% of its drug development and future

Appendix

Diversified and Proven Drug Delivery Platforms

- Outstanding drug delivery platforms to tackle key challenges in the formulation, in **various dosage forms** (e.g. capsules, tablets, sachets or **oral** liquid suspensions; or **injectable** for subcutaneous administration) of a broad range of drugs (already-marketed, off-patent or novel)



Micropump® Platform at a Glance

- Extended/delayed-release of drugs in the GI tract
- Precise pharmacokinetics of single or combination of drugs in various formats
- Numerous Micropump®-based products successfully tested in human clinical trials

Micropump Microparticles for Controlled/Modified Release



- Microparticles are dispersed in the stomach and pass into the small intestine, after which each microparticle releases the drug at an adjustable rate and over an extended period of time (up to 24 hours)
- Drug released at an adjustable rate controlled and/or delayed
- Micropump® microparticles can be used separately or together to provide highly specialized delivery profiles

LiquiTime® Platform at a Glance

LiquiTime® is a novel, proprietary and innovative delivery platform allowing the stable **Liquid** and **controlled release** formulation of one or several combined drugs over **Time**

LiquiTime® meets challenges faced in the treatment of pediatric and geriatric patients and patient populations who have difficulty swallowing tablets or capsules, and may provide better patient compliance



This graph illustrates the different near zero-order release profiles which can be tailored for the same drug

LiquiTime's versatility allows **once- or twice-daily liquid formulations** of a wide variety of drugs

LiquiTime® for Extended-Release Liquid Suspension

Liquid suspension contains small coated drug microparticles
A dose typically contains 5,000 to 50,000 particles

ER microparticles are suspended in the liquid medium

Granules
drug granulate or layered neutral core



Coating
- controls diffusion
- keeps its integrity
- offers good resistance to stress

Each microparticle is individually coated and behaves as an independent micro reservoir

Trigger Lock™ Platform at a Glance

Trigger Lock™ is a proprietary and innovative delivery platform that enables the **controlled release of narcotic and opioid analgesics while deterring their abuse**

Trigger Lock™ successfully addresses the issues of narcotic/opioid analgesics tampering:

- ✓ The sustained release Micropump®-based microparticles are resistant to crushing: each microparticle retains its polymer coating which is virtually impervious to further crushing
- ✓ Trigger Lock™ resists extraction attempts (even in boiling liquids) with beverages (alcoholic or not) preventing injection
- ✓ Trigger Lock™ preserves the bioavailability of the narcotic/opioid analgesics
- ✓ Trigger Lock™ is compatible with different dosage forms (capsules, tablets)

Trigger Lock™ SR Microparticles for Abuse Resistance

1. **Drug loaded Micropump® microparticles**
   Sustained Release (SR) microparticles which are resistant to crushing

2. **Viscosifying ingredient(s)**
   To prevent abuse by injection after extraction in a small volume of solvent

3. **Quenching ingredient(s)**
   To prevent extraction in large volumes of liquid

- Each microparticle retains its polymer coating which is virtually impervious to further crushing

Medusa™ Platform at a Glance



Medusa™ Depot for Injection

- Made of polyglutamic acid and Vitamin E
- Amphiphilic and spontaneously forms stable nanoparticles in water
- Complexes are stable over a wide range of pH



Formulation by simple mixing in water
Non-covalent association
(reversible hydrophobic and/or electrostatic interaction)
of the drug with Medusa™ nanoparticles

In vivo depot formation

Sustained release of the unmodified drug over 1 to 7 days

In Vitro

In Vivo

Reconciliation of Non GAAP to GAAP Results

		Operating Income (Loss)		Net Income (Loss)		Diluted Earnings (Loss) per share	
		2015	2014	2015	2014	2015	2014
Reported		**$ 71.4**	$ (93.9)	**$ 40.7**	$ (84.9)	**$ 0.93**	$ (2.34)
Exclude:	Contingent consideration - Acquisition-related fair value remeasurements - Inc./(Dec.)	**31.0**	57.5	**31.0**	57.5	**0.71**	1.59
	Contingent consideration - Financing-related fair value remeasurements - Inc./(Dec.)	*n/a*	*n/a*	**4.8**	3.5	**0.11**	0.10
	Intangible asset amortization	**12.6**	11.8	**12.6**	11.8	**0.29**	0.32
	Unrealized foreign exchange (gain)/loss	*n/a*	*n/a*	**(6.8)**	(11.7)	**(0.15)**	(0.32)
	Loss on early repayment of related party acquisition-related note	-	3.0	-	3.0	-	0.08
	Loss on early repayment of related party facility agreement notes	*n/a*	*n/a*	-	4.7	-	0.13
	Net income from discontinued operations	*n/a*	*n/a*	-	(4.0)	-	(0.11)
Include:	Contingent consideration - Acquisition-related paid/accrued	**(32.2)**	(1.7)	**(32.2)**	(1.7)	**(0.74)**	(0.05)
	Contingent consideration - Financing-related paid/accrued	*n/a*	*n/a*	**(4.4)**	(0.2)	**(0.10)**	(0.01)
Income tax expense (benefit) related to all above adjustments		*n/a*	*n/a*	**(2.6)**	(2.6)	**(0.06)**	(0.07)
Total adjustments		**11.4**	70.6	**2.4**	60.3	**0.06**	1.66
Adjusted		**$ 82.8**	$ (23.3)	**$ 43.1**	$ (24.6)	**$ 0.99**	$ (0.68)

Free Cash Flow:		2015	2014
Net cash provided by (used in) operating activities		**$ 84.3**	$ (10.6)
Less:	Purchases of property and equipment	**(1.6)**	(1.7)
	Earn-out payments for related party acquisition-related contingent consideration	**(24.6)**	(1.4)
Free Cash Flow		**$ 58.1**	$ (13.7)

Specialty Pharmaceutical Company with Proprietary Drug Delivery Platforms Focused on Improved or Cost-Effective Products

Headquarters

33 avenue du Dr. Georges Levy
69200 Vénissieux (Lyon)
France

Corporate Contact

Phone: +33 472 783 434
Fax: +33 472 783 435
E-mail: licensing@flamel.com

U.S. Commercial Operations

16640 Chesterfield Grove Road, Suite 200
Chesterfield, MO
Phone: 636 449 1830
Fax: 636 449 1850

Exhibit 99.2

Flamel Technologies to Present at the 28th Annual ROTH Conference

Lyon, France – March 8, 2016 - Flamel Technologies (NASDAQ: FLML) today announced that management will be presenting at the 28th Annual ROTH Conference to be held in Dana Point, California, March 13 – 16, 2016. Michael Anderson, Chief Executive Officer of Flamel, is scheduled to present on March 14th at 10:00 a.m. Pacific Time.

Mr. Anderson's presentation will be webcast live and can be accessed by visiting the Investor section of the Company's website at http://www.flamel.com/investors. A replay of the presentation will also be available and archived on the website following the event.

About Flamel Technologies:
Flamel Technologies SA (NASDAQ: FLML) is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently markets two previously Unapproved Marketed Drugs ("UMDs") in the United States, Bloxiverz® (neostigmine methylsulfate injection) and Vazculep® (phenylephrine hydrochloride injection), and in September 2015 announced that the NDA for its third UMD filing was accepted by the FDA and assigned a PDUFA date of April 30, 2016. The Company also develops products utilizing its proprietary drug delivery platforms, Micropump® (oral sustained release microparticles platform), along with its tangent technologies, LiquiTime® (a Micropump-derivative platform for liquid oral products) and Trigger Lock™ (a Micropump-derivative platform for abuse-resistant opioids). Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology, particularly suited to the development of subcutaneously administered formulations. Current applications of Flamel's drug delivery products include sodium oxybate (Micropump®), extended-release of liquid medicines such as ibuprofen and guaifenesin (LiquiTime®, through a license arrangement with Elan Pharma International Limited for the U.S. Over-the-Counter market) and a current study of the delivery of exenatide utilizing the Medusa™ technology. In February 2016, Flamel acquired FSC Pediatrics, a Charlotte, North Carolina-based company that markets three pediatric pharmaceutical products Cefaclor for oral suspension, indicated for infection, Karbinal™ ER, indicated for allergic rhinitis and AcipHex® Sprinkle™ (rabeprazole sodium) indicated for the treatment of gastroesophageal disease (GERD). FSC also received 510(k) clearance from the FDA in October 2015 for Flexichamber ™, a collapsible holding chamber for used in the administration of aerosolized medication using pressurized Metered Dose Inhalers (pMDIs) for the treatment of asthma. The Company is headquartered in Lyon, France and has operations in Dublin, Ireland and in the USA in both St. Louis, Missouri and Charlotte, North Carolina. Additional information may be found at www.flamel.com.

****

Contact: **Michael S. Anderson**
Chief Executive Officer
Phone: (636) 449-1830
E-mail: anderson@flamel.com

Michael F. Kanan
Chief Financial Officer
Phone: (636) 449-1844
E-mail: kanan@flamel.com

Investor Relations
Stephanie Carrington
ICR Inc.
Phone: (646) 277-1282
Email: stephanie.carrington@icrinc.com

Lauren Stival
ICR Inc.
Phone: (646) 277-1287
Email: lauren.stival@icrinc.com